UNSPSC 51461531: Cinnamomum

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S29HWU6QB, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18174 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Magnolianae, Order Laurales, Family Lauraceae, Genus Cinnamomum Schaeff. (cinnamon), commonly known as CINNAMON or as here, CINNAMOMUM.

UNSPSC 51461531 Cinnamomum is a Commodity code under which state and local governments procure generic pharmaceutical products and over-the-counter items through cooperative purchasing vehicles. Recent solicitations show that state and local entities use this code to establish multi-source pharmaceutical supply contracts covering branded and generic medications, dietary supplements, and OTC products distributed across health departments, correctional facilities, hospitals, and other public health infrastructure. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a primary issuing body under this code, leveraging multi-state participation to consolidate purchasing power across participating jurisdictions including Oregon. Vendors responding to pharmaceutical procurement under this code must meet stringent regulatory and operational requirements, including cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA approval, contractual relationships with authorized wholesalers, and comprehensive insurance coverage ($5 million commercial general liability, $2 million network security and privacy liability, $2 million professional liability). Product submissions require detailed specification data—National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, packaging configurations, and manufacturing locations—with pricing offered through flat price, net price, or WAC-minus structures.

MMCAP's RFP S1070000015802 for Generic Multi-Source Pharmaceuticals and OTC Products, due March 26, 2026, represents active procurement under this code. The evaluation emphasizes price competitiveness (75 percent weight) alongside compliance with administrative fee formats (5 percent), EDI capability (5 percent), fixed pricing commitment (10 percent), and acceptance of a 3 percent administrative fee (5 percent); awarded vendors will supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., with contracts effective July 1, 2026, for two years plus optional extensions. The solicitation does not identify specific set-aside designations or disadvantaged-enterprise restrictions based on available documentation. Minnesota and participating multi-state members including Oregon drive recent activity under this code, with cooperative purchasing structures broadening geographic reach beyond single-jurisdiction procurement.